Document is current
Any future updates will be listed below
-
Authors
Spencer, Alexandra J. https://orcid.org/0000-0001-7958-6961
McKay, Paul F. https://orcid.org/0000-0001-5195-6254
Belij-Rammerstorfer, Sandra
Ulaszewska, Marta
Bissett, Cameron D.
Hu, Kai https://orcid.org/0000-0002-5684-1373
Samnuan, Karnyart
Blakney, Anna K. https://orcid.org/0000-0002-5812-9689
Wright, Daniel https://orcid.org/0000-0002-8114-1838
Sharpe, Hannah R. https://orcid.org/0000-0002-1194-2429
Gilbride, Ciaran
Truby, Adam
Allen, Elizabeth R. https://orcid.org/0000-0002-6406-4834
Gilbert, Sarah C. https://orcid.org/0000-0002-6823-9750
Shattock, Robin J. https://orcid.org/0000-0002-4936-1718
Lambe, Teresa https://orcid.org/0000-0001-7711-897X
- License Information
-
More Information
Article History
Received: 28 January 2021
Accepted: 19 April 2021
First Online: 17 May 2021
Competing interests
: S.C.G. is the co-founder and board member of Vaccitech (collaborators in the early development of this vaccine candidate), and is named as an inventor on a patent covering the use of ChAdOx1-vectored vaccines and a patent application covering this SARS-CoV-2 vaccine. T.L. is named as an inventor on a patent application covering this SARS-CoV-2 vaccine and was consultant to Vaccitech. P.M.K. and R.J.S. are co-founders and R.J.S. is a board member of VaxEquity and VacEquity, and are named inventors on a patent application covering the SARS-CoV-2 saRNA vaccine candidate.
